{"id":7918,"date":"2025-07-28T23:00:37","date_gmt":"2025-07-29T06:00:37","guid":{"rendered":"https:\/\/rakuten-med.com\/us\/?post_type=press_releases&#038;p=7918"},"modified":"2025-07-28T22:39:13","modified_gmt":"2025-07-29T05:39:13","slug":"rakuten-medical-expands-patient-recruitment-to-japan-and-prepares-for-expansion-to-eastern-europe-in-global-phase-3-trial-of-asp-1929-photoimmunotherapy-combined-with-pembrolizumab-for-1l-recurrent-he","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/","title":{"rendered":"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer"},"content":{"rendered":"<div id=\"pl-7918\"  class=\"panel-layout\" ><div id=\"pg-7918-0\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7918-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7918-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<ul>\n<li><strong><em>Over 15 clinical sites in the U.S., Taiwan and now Japan are actively recruiting patients<\/em><\/strong><\/li>\n<li><strong><em>Planned site expansion into Eastern Europe with additional clinical trial sites in Ukraine and Poland<\/em><\/strong><\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7918-1\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7918-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7918-1-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"1\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><b>San Diego, CA \u2014 <\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox\u2122 platform-based photoimmunotherapy, today announced the expansion of its ongoing global Phase 3 trial, ASP-1929-381, to include patient enrollment in Japan. The trial is evaluating ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line therapy for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 \/ Acronym: ECLIPSE \/ ClinicalTrials.gov Identifier: <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06699212\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">NCT06699212<\/span><\/a><span style=\"font-weight: 400\">).<\/span><\/p>\n<p><span style=\"font-weight: 400\">Currently, over 15 clinical sites across the United States, Taiwan and Japan are actively recruiting patients. Additional sites are expected to be activated in these regions. To further accelerate recruitment, Rakuten Medical also plans to expand the study to Eastern Europe, with new sites to be activated in Ukraine and Poland in the near future.<\/span><\/p>\n<p><span style=\"font-weight: 400\">This global Phase 3 trial builds upon encouraging data from an <\/span><a href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2024\/05\/24\/7847\/\"><span style=\"font-weight: 400\">interim evaluation<\/span><\/a><span style=\"font-weight: 400\"> \u00a0(data cut-off: August 31, 2023) of 19 patients enrolled in the HNSCC cohort of a Phase 1b\/2 study (ASP-1929-181\/ClinicalTrials.gov Identifier: NCT04305795). That study evaluated ASP-1929 photoimmunotherapy in combination with anti-PD-1 including pembrolizumab in patients with recurrent or metastatic HNSCC. The data showed an estimated 24-month survival rate of 52.4%, with a median OS not yet reached, and a generally manageable safety profile.\u00a0\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">\u201cOur global Phase 3 study is making solid progress across the U.S., Taiwan, and Japan,\u201d said Mickey Mikitani, Chief Executive Officer of Rakuten Medical.<\/span> <span style=\"font-weight: 400\">\u201cTo further accelerate enrollment, we are expanding our network of study sites and preparing to roll out new sites in Ukraine and Poland. Designed for widespread accessibility, our device is portable and cost-effective. We believe our therapy has the potential to make a meaningful contribution to societies worldwide, including those with emerging healthcare systems and considerable unmet needs in oncology.\u201d<\/span><\/p>\n<p><span style=\"text-decoration: underline\"><b>About ASP-1929-381 Study<br \/>\n<\/b><\/span><span style=\"font-weight: 400\">The ASP-1929-381 study is a multi-regional multi-center, randomized, open-label Phase 3 trial, designed to assess the efficacy and safety of ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for locoregional recurrent HNSCC without distant metastases. 412 patients globally will be randomized to either an experimental arm receiving ASP-1929 photoimmunotherapy in combination with pembrolizumab, or a control arm receiving the current pembrolizumab-based standard of care (SOC), where patients may receive pembrolizumab alone or in combination with chemotherapy according to the physician's choice.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">The primary endpoint is Overall Survival (OS), with key secondary endpoints including Complete Response Rate (CRR) and Overall Response Rate (ORR).<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7918-2\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7918-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7918-2-0-0\" class=\"so-panel widget widget_sow-image panel-first-child panel-last-child\" data-index=\"2\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-image so-widget-sow-image-default-8b5b6f678277-7918\"\n\t\t\t\n\t\t>\n<div class=\"sow-image-container\">\n\t\t<img \n\tsrc=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png\" width=\"1280\" height=\"720\" srcset=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png 1280w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map-300x169.png 300w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map-1024x576.png 1024w, https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map-768x432.png 768w\" sizes=\"(max-width: 1280px) 100vw, 1280px\" title=\"EN-2025-07_381 site map\" alt=\"\" \t\tclass=\"so-widget-image\"\/>\n\t<\/div>\n\n<\/div><\/div><\/div><\/div><div id=\"pg-7918-3\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7918-3-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7918-3-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"3\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><i><span style=\"font-weight: 400;\">Disclaimer: Rakuten Medical\u2019s Alluminox\u2122 platform-based photoimmunotherapy is investigational outside Japan.<\/span><\/i><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7918-4\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7918-4-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7918-4-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"4\" ><div class=\"panel-widget-style panel-widget-style-for-7918-4-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><b>About Rakuten Medical, Inc.<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox\u2122 platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical\u2019s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries\/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit <\/span><a href=\"http:\/\/www.rakuten-med.com\"><span style=\"font-weight: 400\">www.rakuten-med.com<\/span><\/a><span style=\"font-weight: 400\">.<\/span><\/p>\n<p><b>About Alluminox\u2122 platform<br \/>\n<\/b><span style=\"font-weight: 400\">The Alluminox\u2122 platform is Rakuten Medical\u2019s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye\u00ae 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical\u2019s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and\/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical\u2019s Alluminox platform-based photoimmunotherapy is investigational.<\/span><\/p>\n<p><b>About ASP-1929<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical\u2019s first pipeline drug developed on its Alluminox\u2122 platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye\u00ae 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority.<\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div id=\"pg-7918-5\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-7918-5-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7918-5-0-0\" class=\"so-panel widget widget_sow-button panel-first-child panel-last-child\" data-index=\"5\" ><div style=\"padding: 30px 0px 0px 0px;\" class=\"panel-widget-style panel-widget-style-for-7918-5-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-button so-widget-sow-button-flat-6fd36f18507f-7918\"\n\t\t\t\n\t\t><div class=\"ow-button-base ow-button-align-center\"\n>\n\t\t\t<a\n\t\t\t\t\thref=\"https:\/\/rakuten-med.com\/us\/contact\/\"\n\t\t\t\t\tclass=\"rakuten-btn sowb-button ow-icon-placement-left ow-button-hover\" \t>\n\t\t<span>\n\t\t\t\n\t\t\tContact Us\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Over 15 clinical sites in the U.S., Taiwan and now Japan are actively recruiting patients Planned site expansion into Eastern [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":7919,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7918","1":"press_releases","2":"type-press_releases","3":"status-publish","4":"has-post-thumbnail","6":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"Over 15 clinical sites in the U.S., Taiwan and now Japan are actively recruiting patients Planned site expansion into Eastern [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/\",\"name\":\"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/07\\\/EN-2025-07_381-site-map.png\",\"datePublished\":\"2025-07-29T06:00:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/#primaryimage\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/07\\\/EN-2025-07_381-site-map.png\",\"contentUrl\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/07\\\/EN-2025-07_381-site-map.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2025\\\/07\\\/28\\\/7918\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.","og_description":"Over 15 clinical sites in the U.S., Taiwan and now Japan are actively recruiting patients Planned site expansion into Eastern [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/","og_site_name":"Rakuten Medical - To conquer cancer.","og_image":[{"width":1280,"height":720,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/","url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/","name":"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/#primaryimage"},"image":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/#primaryimage"},"thumbnailUrl":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png","datePublished":"2025-07-29T06:00:37+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/#primaryimage","url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png","contentUrl":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2025\/07\/EN-2025-07_381-site-map.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2025\/07\/28\/7918\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten Medical Expands Patient Recruitment to Japan and Prepares for Expansion to Eastern Europe in Global Phase 3 Trial of ASP-1929 Photoimmunotherapy Combined with Pembrolizumab for 1L Recurrent Head and Neck Cancer"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases\/7918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/press_releases"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/2"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media\/7919"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}